Document:

Change in Control Policy

 Exhibit 10.7 

 
 

 
  
 

 
 Change in Control 
 Policy 

 Table of Contents 
  

							
			
	 1.
	 	Introduction	  	 	3	  
			
	 1.1
	 	 Overview
	  	 	3	  
			
	 1.2
	 	 Purpose of the Policy
	  	 	3	  
			
	 1.3
	 	 Policy Objectives
	  	 	3	  
			
	 1.4
	 	 Scope
	  	 	3	  
			
	 2.
	 	Policy	  	 	3	  
			
	 2.1
	 	 Policy Statement & Description
	  	 	3	  
			
	 2.2
	 	 Roles and Responsibilities
	  	 	4	  
			
	 3.
	 	Appendix	  	 	4	  
			
	 3.1
	 	 Glossary
	  	 	4	  
			
	 3.2
	 	 Related Policies & Regulations
	  	 	6	  

  

			
	 PartnerRe
 Change
in Control Policy
	 	2

 March 2012

	1.	Introduction 

  

	1.1	Overview 

 The PartnerRe Ltd. Change in
Control Program (“CIC Program”) protects the salary and benefits of certain key executives in situations a change in control has occurred and the key executive has terminated employment within 12 months of such event. 

 

	1.2	Purpose of the Policy 

 The purpose of the
CIC Program is to secure the continued services of key executives of the Company and to ensure their continued dedication to their duties in the event of, or the threat of a Change in Control. 

 

	1.3	Policy Objectives 

  

	–	To provide incentives to ensure key executives act in the best interests of shareholders in the event of a Change in Control: and 

 

	–	To provide protection to key executives who may be asked to defend against hostile takeovers 

 

	1.4	Scope 

 This CIC Program is intended to
apply to certain key executives, as approved by the Compensation and Management Development Committee (“Participants”), and will be managed and administered by Group Compensation and Benefits. 

 

	2.	Policy 

  

	2.1	Policy Statement & Description 

CIC Award Conditions 
 Participants are
entitled to CIC award provisions under the following conditions: 
  

	-	CIC, as defined herein, has occurred within the last 12 months. 

  

	-	The Participant is terminated by the Company for reasons other than death, disability or “Cause” or the Participant terminates with “Good Reason”,
as defined herein, during the CIC Transition Period. 

  

			
	 PartnerRe
 Change
in Control Policy
	 	3

 March 2012

 CIC Award Provisions by Tier Level 
 The CIC award provisions for each Participant are defined by the tier level of the Participant. 
  

							
	 	  	 Tier 1
	  	 Tier 2
	  	 Tier 3

	 Award Provisions
	  	Group Chief Executive Officer	  	Executive Committee Member	  	Other
				
	 Base Salary
	  	3 times annual	  	2 times annual	  	1 time annual
				
	 Cash Annual Incentive (1)
	  	3 times	  	2 times	  	1 time
				
	 Prorata Target Cash Annual Incentive (2)
	  	1	  	1	  	0
				
	 Health and Welfare
	  	3 years	  	2 years	  	
		
	 Other Benefits
	  	As per individual contracts

  

	(1)	The greater of the average annual incentive paid in each of the 3 years prior to the Change in Control or the target annual incentive for current role;

	(2)	Prorated for year of termination 

  

	2.2	Roles and Responsibilities 

 The
Compensation and Management Development Committee approves this Policy. The Change in Control Policy will be managed and administered by Group Compensation and Benefits. 

 

	3.	Appendix 

  

	3.1	Glossary 

  

			
	 Terms
	  	 Definitions

	 Change in Control or CIC
	  	(i) when any “person” within the meaning of Section 14(d) of the Securities Exchange Act of 1934 (the “Exchange Act”), other than the PartnerRe Ltd. (the
“Company”), a subsidiary or any employee benefit plan(s) sponsored by the

  

			
	 PartnerRe
 Change
in Control Policy
	 	4

 March 2012

			
	 Terms
	  	 Definitions

		  	 Company or any subsidiary, is or becomes the “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly
or indirectly, of fifty percent (50%) or more of the then outstanding Common Shares; or
  
 (ii) at any time during a period of 12 consecutive months, when individuals who constitute the Board on the effective date of this Policy, cease for any reason to constitute at least a majority thereof,
provided that any person becoming a director subsequent to the effective date of this definition, whose election, or nomination for election by the Company’s shareholders, was on the recommendation or with the approval of at least two-thirds of
the directors comprising the Board on the effective date of this definition (either by a specific vote or by approval of the proxy statement of the Company in which such person is named as a nominee for director, without objection to such
nomination) shall be, for purposes of this clause (ii), considered as though such person were a member of the Board on the effective date of this definition;
  

(iii) all or substantially all of the assets of the Company are sold, liquidated or distributed (in one or a series of related transactions);
or
  
 (iv) there occurs a reorganization, merger, consolidation or other
corporate transaction involving the Company (a “Transaction”), other than with a wholly-owned subsidiary and other than a merger or consolidation, that would result in the voting securities of the Company outstanding immediately prior
thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more than 50% of the combined voting power of the voting securities of the Company or such surviving entity
outstanding immediately after such Transaction.

		
	 Cause
	  	The Company shall have “Cause” to terminate the Participant’s employment hereunder upon (A) the engaging by the Participant in serious negligence or willful
misconduct which is demonstrably injurious to its subsidiaries; (B) willful and intentional failure to comply in all

  

			
	 PartnerRe
 Change
in Control Policy
	 	5

 March 2012

			
	 Terms
	  	 Definitions

		  	material respects with the direction of the Board after written notice and the opportunity to correct, or (C) the conviction, a plea of guilty or a plea of no contest of the
Participant for a serious criminal act. For purposes of this paragraph, no act, or failure to act, on the Participant’s part shall be considered “willful” unless done, or omitted to be done, by him not in good faith and without
reasonable belief that his action or omission was in the best interest of the Company.
		
	 Good Reason
	  	Good Reason” shall mean (A) a failure by the Company to comply with any material provision of the Participant’s Employment Agreement, (B) the assignment to the
Participant by the Company of duties inconsistent in a material adverse respect with the Participant’s position, authority, duties or responsibilities with the Company, as applicable, including, but not limited to, any reduction whatsoever in
such position, authority, duties, responsibilities or status, or a change in the Participant’s titles as then in effect, (C) without the Participant’s prior written consent, any reduction in Base Salary and annual benefits, (D) change in
the condition of employment.
		
	 CIC Transition Period
	  	 The period following the Change in Control during which CIC award provisions may be claimed by a Participant under specific
conditions as outlined herein.
  
 The CIC Transition Period for all
Participants is 12 months following the date of the CIC.

  

	3.2	Related Policies & Regulations 

The Change in Control sections of the Equity Plan documents. 

  

			
	 PartnerRe
 Change
in Control Policy
	 	6

 March 2012Amendment No. 1 to Consulting Agreement

 Exhibit 10.43 
 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION (THE “COMMISSION”) PURSUANT TO
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 Confidential 

AMENDMENT NO. 1 TO CONSULTING AGREEMENT 
 Cytokinetics, Inc. (“Cytokinetics”) and David J. Morgans, Jr., PhD (“Consultant”) have entered into that certain Consulting Agreement dated November 1, 2011 (the
“Agreement”) . Cytokinetics and Consultant now wish to amend the Agreement, as set forth below in this “Amendment”, effective May 1, 2012. Capitalized terms used herein and not otherwise defined herein will have the
meaning ascribed in the Agreement. 
 Cytokinetics and Consultant hereby agree as follows: 

 

	 	1.	The Agreement is extended for an additional term to expire on October 31, 2012. 

 

	 	2.	Section 1.3 of the Agreement is revised to read as follows: 

 “Consultant will provide the Services over the telephone or through written or electronic correspondence as requested by the Company, and will make himself available in person at the Company’s
offices or other agreed locations for 4 days per month at mutually agreeable times.” 
  

	 	3.	Section 3.1 of the Agreement is hereby revised to read as follows: 

 “From May 1, 2012 through October 31, 2012, for services provided by Consultant under this Agreement, the Company will pay to Consultant a monthly retainer of $7,760 as compensation for the 4 days of
on-site consulting described in Section 1.3. Payment of the retainer will be paid monthly in advance on the first AP run of the month. In addition the Company will pay Consultant for additional Services at a rate of $242.50 per hour. These
additional hours must be approved by Cytokinetics (which may be provided by e-mail) in advance and in no calendar month may Consultant charge the Company for more than $12,500 (inclusive of the retainer) without the further express written consent
of Company (which may be provided by e-mail). Consultant shall provide the Company with a written invoice semi-monthly, which shall described the activities performed and the time spent by Consultant on such activities. Proper invoices shall be paid
by Cytokinetics within (30) days of receipt. Time spent by the Consultant on travel is not compensable. Invoices will be sent to the attention of Accounts Payable. 
  

	 	4.	Exhibit A of the Agreement is replaced with Exhibit A attached to this Amendment. 

 

	 	5.	Except as expressly set forth herein, all of the terms of the Agreement will remain in full force and effect. 

Accepted and agreed: 
  

							
	CYTOKINETICS, INC.	 	CONSULTANT
		
	 By: /s/ Robert I.
Blum                                         
             
	 	By:         /s/ David J.
Morgans                                        
        
		
	Print Name: Robert I.
Blum                                         
     	 	Print Name:          David J. Morgans, Jr.,
Ph.D                       
		
	Title:     President &
CEO                                    	 	
		
	Date:     
4/23/12                                        
                        	 	Date:
                  4/24/12                      
                                     

  

  
 Page 1 of 2

  
  
 EXHIBIT A 
 SERVICES AND DELIVERABLES 

 
  

[***] 
  

 
  
 ***
Certain information on the page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

 

  
 Page 2 of 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00203-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00203-of-00352.parquet"}]]